Results of the Expert Forum on the application of perampanel in routine clinical practice
https://doi.org/10.17749/2077-8333/epi.par.con.2020.036
Abstract
In February 2020, in Moscow, Expert Forum was held on the issues of the application of perampanel in routine clinical practice. The main aim of the Forum was to discuss the tolerance and safety profile of perampanel in patients with epilepsy in different age and gender groups in the conditions of routine clinical practice. Leading experts in neurology and epileptology took part in the Forum, wherein the acute data on the efficiency and safety of perampanel and the management of potential risks were presented.
Keywords
perampanel,
epilepsy,
effective dosing,
titration,
cognitive impairments,
risk of falling,
drowsiness,
dizziness
Supporting agencies: The publication was financed by Eisai company.
References
1. Perampanel. Instructions for medical use. State Register of Medicines [Electronic resource] URL: http://www.grls.rosminzdrav.ru. Accessed: 02.19.2020. (In Russ.)
2. Avakyan G. N., Blinov D. V., Lebedeva A. V., Burd S. G., Avakyan G. G. ILAE classification of the epilepsies: the 2017 revision and update. Epilepsy and paroxysmal conditions. 2017; 9 (1): 6–25. (In Russ.) DOI: https://doi.org/10.17749/2077-8333.2017.9.1.006-025.
3. Rogawski M. A., Löscher W. The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience. 2004 Jul; 5 (7): 553–64.
4. Rogawski M. A. Revisiting AMPA Receptors as an Antiepileptic Drug Target: Revisiting AMPA Receptors as an Antiepileptic Drug Target. Epilepsy Currents. 2011 Mar; 11 (2): 56–63.
5. Collingridge G. L., Olsen R. W., Peters J., Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology. 2009 Jan 1; 56 (1): 2–5.
6. Engel J., Pedley T. A., Aicardi J., editors. Epilepsy: a comprehensive textbook. Lippincott Williams & Wilkins; 2008.
7. Hanada T., Hashizume Y., Tokuhara N., Takenaka O., Kohmura N., Ogasawara A., Hatakeyama S., Ohgoh M., Ueno M., Nishizawa Y. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011 Jul; 52 (7): 1331–40.
8. Kenakin T. Allosteric modulators: the new generation of receptor antagonist. Molecular interventions. 2004 Aug 1; 4 (4): 222–229.
9. Sarro G. D., Gitto R., Russo E., Ibbadu G. F., Barreca M. L., Luca L. D., Chimirri A. AMPA receptor antagonists as potential anticonvulsant drugs. Current topics in medicinal chemistry. 2005 Jan 1; 5 (1): 31–42.
10. Kamiński R. M., Van Rijn C. M., Turski W. A., Czuczwar S. J., Van Luijtelaar G. AMPA and GABAB receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. European journal of pharmacology. 2001; 430 (2–3): 251–9.
11. Steinhoff B. J., Ben-Menachem E., Ryvlin P., Shorvon S., Kramer L., et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013; 54: 1481–9.
12. Ettinger A. B., LoPresti A., Yang H., Williams B., Zhou S., et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015; 56: 1252–63.
13. French J. A., Krauss G. L., Wechsler R. T., Wang X-F., DiVentura B., et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology. 2015; 85: 950–7.
14. Villanueva V., Garcés M., López-González F.J., Rodriguez-Osorio X., Toledo M., Salas-Puig J., González-Cuevas M., Campos D., Serratosa J. M., González-Giráldez B., Mauri J. A. Safety, efficacy and outcome-related factors of perampanel over 12 months in a realworld setting: the FYDATA study. Epilepsy research. 2016; 126: 201–210.
15. Meador K. J., Yang H., Piña-Garza J.E., Laurenza A., Kumar D., Wesnes K. A. Cognitive effects of adjunctive perampanel for partialonset seizures: a randomized trial. Epilepsia. 2016 Feb; 57 (2): 243–51.
16. Rea R.,Traini E., Renna R., Pagliuca F., Pezzella M.,Pagliuca M. Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy: a retrospective study. Epilepsy & Behavior. 2019; 98: 139–144.
17. Meschede C., Witt J. A., Rademacher M., von Wrede R. D., Elger C. E., Helmstaedter C. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure. 2018; 58: 141–146.
18. Fife T. D., Sirven J. Antiepileptic drugs and their impact on balance. Aging Health. 2005; 1 (1): 147–155.
19. Zaccara G., Gangemi P. F., Cincotta M. Central nervous system adverse effects of new antiepileptic drugs: a meta-analysis of placebocontrolled studies. Seizure. 2008; 1; 17 (5): 405–421.
20. Sirven J. I., Fife T. D., Wingerchuk D. M., Drazkowski J. F. Secondgeneration antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clinic Proceedings. 2007; 82 (1): 40–47.
21. Leppik I. E., Yang H., Williams B., Zhou S., Fain R., Patten A., Bibbiani F., Laurenza A. Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies. Epilepsia. 2017; 58 (1): 51–59.
22. Trinka E., Steinhoff B. J., Nikanorova M., Brodie M. J. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand. 2016; 133 (3): 160–172.
23. Rocamora R., Álvarez I., Chavarría B., Principe A. Perampanel effect on sleep architecture in patients with epilepsy. Seizure. 2020; 1 (76): 137–42.
24. Steinhoff B. J., Ben-Menachem E., Ryvlin P., Shorvon S., Kramer L., Satlin A., Squillacote D., Yang H., Zhu J., Laurenza A. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013 Aug; 54 (8): 1481–9.
25. Jaramillo J. A., María J. C., Úbeda J. M., López Ó. V., Rivas M. E., Díaz H. P., Martín G. G., Herrero E. V., Chamorro-Muñoz M., Vázquez F., De la Fuente C. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON). Epilepsy & Behavior. 2020; 1 (102): 106655.
26. Zhidkova I. A., Karlov V. A., Vlasov P. N. The effectiveness and tolerability of perampanel in everyday clinical practice. Zhurnal nevrologii i psikhiatrii im. Korsakova. 2016; 9 (2): 74–80 (in Russ.).
27. Karlov V. A. Epilepsy in children and adult women and men. A guide for doctors. Second edition. Moscow. 2019 (in Russ.).
28. Agrawal Y., Carey J. P., Della et al. Disorders of balance and vestibular function in US adults: data from the National Health and Nutrition Examination Survey, 2001-2004. Arch Intern Med. 2009; 169 (10): 938.
29. Krauss G. L., Perucca E., Kwan P., Ben-Menachem E., Wang X. F., Shih J. J., Patten A., Yang H., Williams B., Laurenza A. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. Epilepsia. 2018; 59 (4): 866–876.
30. Villanueva V., Montoya J., Castillo A., Mauri-Llerda J.Á., Giner P., López-González F.J., Piera A., Villanueva-Hernández P., Bertol V., Garcia-Escrivá A., Garcia-Peñas J. J. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. Epilepsia. 2018; 59 (9): 1740–1752.
31. Pickrell W. O., Lacey A. S., Thomas R. H., Smith P. E., Rees M. I. Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013 Jul 1; 84 (7): 796–9.
32. Ben-Menachem E. Weight issues for people with epilepsy – a review. Epilepsia. 2007 Dec; 48: 42–5.
33. Lagae L., Belousova E., Carroll K. et al. The effect of perampanel on weight change in adolescents with refractory focal epilepsy. Poster presented at the 68th Annual Meeting of the American Epilepsy Society, Washington, DC, USA, December 5–9, 2014.
34. Yang H., Laurenza A., Williams B., Patten A., Hussein Z., Ferry J. Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Epilepsy research. 2015; 114: 122–30.
35. Genton P. When antiepileptic drugs aggravate epilepsy. Brain and Development. 2000; 22 (2): 75–80.
36. O’Brien T.J. et al. Poster presented at EAN. 2015.
Review
For citations:
Results of the Expert Forum on the application of perampanel in routine clinical practice. Epilepsy and paroxysmal conditions. 2020;12(2):125-132. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2020.036
Views: 698
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
